When to initiate combined antiretroviral therapy to reduce mortality and aids-defining illness in HIV-infected persons in developed countries

Annals of Internal Medicine

Volumn 154, Issue 8, 2011, Pages 509-515

  Cain, L E ^a   Logan, R ^a   Robins, J M ^a   Hernan M A ^a   Sterne, J A C ^b   Sabin, C ^c   Bansi, L ^c   Goulet, J ^d   Justice, A ^d   van Sighem, A ^e   de Wolf, F ^e   Bucher, H C ^f   von Wyl, V ^g   Esteve, A ^h   Casabona, J ^h   del Amo, J ⁱ   Moreno, S ^j   Seng, R ^k   Meyer, L ^k   Perez Hoyos S ^l   Muga, R ^h   Lodi, S ^m   Lanoy, E ⁿ   Costagliola, D ^o   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ CARLOS III INSTITUTE OF HEALTH   (Spain)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k BICÊTRE HOSPITAL   (France)

^l HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^m MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁿ SORBONNE UNIVERSITÉ   (France)

^o INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; EUROPE; FEMALE; HAZARD RATIO; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL; UNITED STATES;

EID: 79955422390     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-154-8-201104190-00001     Document Type: Article

References (45)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-733. [PMID: 9287227]
2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351: 543-549. [PMID: 9492772]
3. Sterne JA, Herna ́n MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al; Swiss HIV Cohort Study. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005;366: 378-384. [PMID: 16054937]
4. Cole SR, Herna ́n MA, Robins JM, Anastos K, Chmiel J, Detels R, et al. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Am J Epidemiol. 2003;158:687-694. [PMID: 14507605]
5. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. [PMID: 18942885]
6. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al; DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735. [PMID: 17460226]
7. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, et al. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS. 2008;22:2371-2380. [PMID: 18981777]
8. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.[PMID: 12126821]
9. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577. [PMID: 11722271]
10. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al; HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626. [PMID: 12693883]
11. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-1197. [PMID: 17502729]
12. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006;166:1632-1641.[PMID: 16908797]
13. Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, et al; UK Collaborative HIV Cohort Study. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS. 2007;21:1717-1721. [PMID: 17690569]
14. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, Porter K, et al; CASCADE Collaboration. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS. 2006;20:741-749. [PMID: 16514305]
15. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. [PMID: 16878047]
16. Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm. J Acquir Immune Defic Syndr. 2007; 44:179-187. [PMID: 17075385]
17. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008;22:2143-153. [PMID: 18832878]
18. European AIDS Clinical Society. Guidelines: Clinical Management and Treatment of HIV-infected Adults in Europe. Paris, France: European AIDS Clinical Society; 2009. Accessed at www.europeanaidsclinicalsociety.orgguidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf on 15 February 2011.
19. World Health Organization. Rapid Advice: Antiretroviral Therapy for HIV Infection in Adults and Adolescents. Geneva: World Health Organization; 2009. Accessed at www.whoint/hiv/pub/arv/rapid_advice_art.pdf on 15 February 2011.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Bethesda, MD: U.S. Department of Health and Human Services; 2009. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 15 February 2011.
21. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333. [PMID: 20639566]
22. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008; 197:1133-1144. [PMID: 18476292]
23. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265. [PMID: 20647201]
24. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al; When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363. [PMID: 19361855]
25. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826. [PMID: 19339714]
26. Strategic Timing of Antiretroviral Treatment. 2009. Accessed at http://insight.ccbr.umn.edu/start/ on 25 Feburary 2011.
27. Anglaret X, Eholie S. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). Accessed at http://clinicaltrials.gov/ct2/show/NCT00495651 on 15 February 2011.
28. Ray M, Logan R, Sterne JA, Hernadez-Ďiaz S, Robins JM, Sabin C, et al; HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24:123-137. [PMID: 19770621]
29. UK Register of HIV Seroconverters (UKRHS) Steering Committee. The UK register of HIV seroconverters: methods and analytical issues. Epidemiol Infect. 1996;117:305-312. [PMID: 8870628]
30. Dalmasso C, Carpentier W, Meyer L, Rouzioux C, Goujard C, Chaix ML, et al; ANRS Genome Wide Association 01. Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One. 2008;3:e3907. [PMID: 19107206]
31. Desquilbet L, Goujard C, Rouzioux C, Sinet M, Deveau C, Chaix ML, et al; PRIMO and SEROCO Study Groups. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS. 2004;18:2361-2369. [PMID: 15622312]
32. Perez-Hoyos S, del Amo J, Muga R, del Romero J, Garćia de Olalla P, Guerrero R, et al; GEMES (Spanish Multicenter Study Group of Seroconverters). Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: differences by transmission category. AIDS. 2003;17:353-359. [PMID: 12556689]
33. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19. [PMID: 1361652]
34. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, et al; EuroSIDA study group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007;370:407-413. [PMID: 17659333]
35. Hernan MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006;98:237-242. [PMID: 16611197]
36. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernan MA.When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostatistics. 2010;6 Article 18.
37. Hernan MA, Hernandez-Ďiaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625. [PMID: 15308962]
38. van der Laan MJ, Petersen ML. Casual effect models for realistic individualized treatment and intention to treat rules. Int J Biostat. 2007;3: Article3. [PMID: 19122793]
39. Orellana L, Rotnizky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, part I: main content. Int J Biostat. 2010;6;Article 7.
40. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656-664. [PMID: 18682488]
41. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826. [PMID: 19339714]
42. Hernan MA, Robins JM. Early versus deferred antiretroviral therapy for HIV [Letter]. N Engl J Med. 2009;361:822-823. [PMID: 19701984]
43. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-454. [PMID: 9466638]
44. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27:4678-4721. [PMID: 18646286]
45. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. [PMID: 17135583]